IDEXX Labs (IDXX) Stock
Key stats
- Market cap
- $52.84B
- Price / Earnings ratio
- 46.6x
- EPS (TTM)
- $14.92
- Volume
- Loading
- 52-week high
- $769.98
- 52-week low
- $500.61
- EPS vs analyst estimate
- +2.5%Q3 FY25 · $3.22 vs $3.14
Source: third-party data provider, as of November 7, 2026
EPS estimate: analyst consensus
Compare with IDXX
Recent news

Idexx Laboratories (IDXX) Crossed Above the 200-Day Moving Average: What That Means for Investors
Idexx Laboratories (IDXX) Crossed Above the 200-Day Moving Average: What That Means for Investors
IDXX

IDEXX Soars 20.2% on Earnings Beat: What It Means for Your S&P 500 Index Fund
IDEXX Soars 20.2% on Earnings Beat: What It Means for Your S&P 500 Index Fund
IDXX

IDEXX raises forecast, betting diagnostics can offset weak vet visits
IDEXX raises forecast, betting diagnostics can offset weak vet visits
IDXX

IDEXX Sales Rise 10% as Margin Outlook Slips: Rapid Earnings Reaction
IDEXX Sales Rise 10% as Margin Outlook Slips: Rapid Earnings Reaction
IDXX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 70.28
- MACD 12/26/9
- 34.71
- EMA 9 of MACD
- 20.60
- MACD histogram
- 14.11
- SMA 50
- $544.13
- Price above SMA 50
- EMA 50
- $562.75
- Price above EMA 50
- SMA 200
- $572.14
- Price above SMA 200
- EMA 200
- $587.43
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $3.73 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Idexx Laboratories (IDXX) Crossed Above the 200-Day Moving Average: What That Means for Investors
Idexx Laboratories (IDXX) Crossed Above the 200-Day Moving Average: What That Means for Investors
IDXX

IDEXX Soars 20.2% on Earnings Beat: What It Means for Your S&P 500 Index Fund
IDEXX Soars 20.2% on Earnings Beat: What It Means for Your S&P 500 Index Fund
IDXX

IDEXX raises forecast, betting diagnostics can offset weak vet visits
IDEXX raises forecast, betting diagnostics can offset weak vet visits
IDXX

IDEXX Sales Rise 10% as Margin Outlook Slips: Rapid Earnings Reaction
IDEXX Sales Rise 10% as Margin Outlook Slips: Rapid Earnings Reaction
IDXX

IDEXX Laboratories Q3 Earnings Call Highlights
IDEXX Laboratories Q3 Earnings Call Highlights
IDXX

Idexx (IDXX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Idexx (IDXX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
IDXX

IDXX Q3 Earnings & Revenues Surpass Estimates, Stock Up in Pre-Market
IDXX Q3 Earnings & Revenues Surpass Estimates, Stock Up in Pre-Market
IDXX

Idexx Labs Barks Up A Third-Quarter Beat; Can It Fetch This Next Bullish Move?
Idexx Labs Barks Up A Third-Quarter Beat; Can It Fetch This Next Bullish Move?
IDXX

Idexx Laboratories (IDXX) Beats Q3 Earnings and Revenue Estimates
Idexx Laboratories (IDXX) Beats Q3 Earnings and Revenue Estimates
IDXX

IDEXX Laboratories Announces Third Quarter Results
IDEXX Laboratories Announces Third Quarter Results
IDXX
News tone: automated (AI) classification of the article's content, not a price prediction.
About IDEXX Labs
IDEXX Laboratories, Inc. is a member of the S&P 500® Index and is a leader in pet healthcare innovation, offering diagnostic and software products and services that deliver solutions and insights to practicing veterinarians around the world. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency, and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry and tests for the quality and safety of water and milk and point-of-care and laboratory diagnostics for human medicine.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael G. Erickson Ph.D. | CEO, President & Director | 1974 |
| Mr. Jonathan J. Mazelsky | Executive Chairman | 1961 |
| Mr. Andrew Emerson | Executive VP, CFO & Treasurer | 1983 |
| Mr. Michael J. Lane | Executive VP and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology | 1968 |
| Dr. Martin Smith Ph.D. | Executive Vice President of Global Operations and R&D | 1968 |
| Mr. Bob Asmann | Senior Vice President of Global Operations | — |
| Mr. Amit Gupta | Senior VP, Chief Digital & Information Officer | — |
| Ms. Sharon E. Underberg J.D. | Executive VP, General Counsel, & Corporate Secretary | 1961 |
| Ms. Julie Godon | Senior VP & Global Marketing Officer | — |
| Mr. Michael P. Johnson | Executive VP & Chief Human Resources Officer | 1978 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 7, 2026
Technical indicators
- RSI 14
- 70.28
- MACD 12/26/9
- 34.71
- EMA 9 of MACD
- 20.60
- MACD histogram
- 14.11
- SMA 50
- $544.13
- Price above SMA 50
- EMA 50
- $562.75
- Price above EMA 50
- SMA 200
- $572.14
- Price above SMA 200
- EMA 200
- $587.43
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $700.00
- Average
- $742.50
- High
- $810.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -4.1 | +9.8 | ||||||||||
| 2022 | -19.6 | +3.7 | +2.2 | -22.2 | -9.4 | -5.1 | +11.4 | -12.7 | -6.9 | +6.8 | +7.8 | -7.1 |
| 2023 | +18.3 | -2.1 | +6.6 | +0.6 | -5.1 | +6.9 | +13.2 | -3.9 | -14.5 | -7.3 | +17.8 | +15.0 |
| 2024 | -6.0 | +9.1 | -6.4 | -7.4 | +6.2 | -1.1 | -0.1 | +0.7 | +7.7 | -17.9 | +1.1 | -4.0 |
| 2025 | +3.2 | -6.8 | -3.9 | +3.4 | +8.9 | +4.2 | -1.5 | +20.8 | -0.1 | +1.5 | +4.1 | -7.2 |
| 2026 | +0.1 | +2.7 | -11.7 | -0.7 | -0.7 | -7.1 | +4.0 | -2.0 | -4.2 | +6.5 | -0.1 |



